Skip to main content
Premium Trial:

Request an Annual Quote

Scope Fluidics Secures €10M Loan From European Investment Bank

NEW YORK — The European Investment Bank (EIB) said on Tuesday that it will lend up to €10 million ($11.8 million) to Polish startup Scope Fluidics to assist with the development of infectious disease diagnostics.

Scope's product pipeline includes a point-of-care molecular diagnostic instrument called PCR One and a related rapid multiplex respiratory virus panel that includes SARS-CoV-2, influenza, and respiratory syncytial virus, as well as an antibiotic susceptibility testing system called BacterOmic that uses hundreds of independent culturing zones within a microfluidic cartridge to determine minimum inhibitory concentrations for antibiotics.

Scope expects to submit PCR One with a SARS-CoV-2 test to the US Food and Drug Administration for Emergency Use Authorization by the end of the year. 

EIB, the lending arm of the European Union, said the loan is being provided to Scope under the Infectious Diseases Financing Facility of the EU's Horizon 2020 research funding program.

In February, Scope raised 14 million Polish zloty ($3.7 million) through a share issuance. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.